Apellis Pharmaceuticals is currently testing the bottom of a key weekly gap near the $20 level, an area that has historically acted as a strong support zone. A confirmed breakout above the $29 level would signal renewed bullish momentum and open the path toward the $35.25 resistance, which aligns with prior supply and structural resistance.
APLS looks primed for a bounce as selling pressure fades and momentum indicators begin to shift upward. With a clearly defined stop-loss at $18.50, this setup offers a strong risk-to-reward profile, giving traders controlled downside and meaningful upside potential.
Fundamentally, positive sentiment continues around Apellis’ commercial rollout of Syfovre and its expanding pipeline in complement inhibition—adding further tailwind to the technical setup.
APLS looks primed for a bounce as selling pressure fades and momentum indicators begin to shift upward. With a clearly defined stop-loss at $18.50, this setup offers a strong risk-to-reward profile, giving traders controlled downside and meaningful upside potential.
Fundamentally, positive sentiment continues around Apellis’ commercial rollout of Syfovre and its expanding pipeline in complement inhibition—adding further tailwind to the technical setup.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.